1 |
Benet, L. (2006). Why highly variable drugs are safer, Meeting of FDA Committee for Pharmaceutical Science, http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4241s22.ppt(assessed 3/17/2011).
|
2 |
Chow, S. C. and Liu, J. (2008). Design and Analysis of Bioavailability and Bioequivalence Studies, Third edition, Chapman & Hall.
|
3 |
Dangi, Y. S., Soni, M. L. and Namdeo, K. P. (2010). Highly variable drugs: Bioequivalence requirements and regulatory perspectives, Journal of Current Pharmaceutical Research, 3, 24-28.
|
4 |
Endrenyi, L. and Tothfalusi, L. (2009). Regulatory conditions for the determination of bioequivalence of highly variable drugs, Journal of Pharmacy & Pharmaceutical Sciences, 12, 138-149.
DOI
|
5 |
Jeong, G. and Park, S. (2011). On Evaluation of Bioequivalence for Highly Variable Drugs, The Korean Journal of Applied Statistics, 24, 1055-1076.
과학기술학회마을
DOI
ScienceOn
|
6 |
IMS Health (2011). IMS Health Report. IMS.
|
7 |
Korea Food & Drug Administration (2012). Regulations of Bioequivalence Trials, Publication No.2012-103.
|
8 |
Jones, B. and Kenward, M. G. (2003). Design and Analysis of Cross-over Design, Second Edition, Chapman & Hall.
|
9 |
Park, S. (2007). On sample size determination of Bioequivalence Trials, Journal of Korean Data & Information Science Society, 18, 365-373.
과학기술학회마을
|
10 |
Schuirmann, D. J. (1987). A comparison of two one-sided tests procedures and the power approach for assessing the bioequivalence trials, Journal of Pharmacokinetics and Biopharmaceutics, 15, 657-680.
DOI
|
11 |
Baek, I., Seong, S. and Kwon, K. (2009). Bioequivalence approaches for highly variable drugs: Issue and solution, Korean Journal of Clinical Pharmacy, 19, 50-60.
과학기술학회마을
|